View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 14, 2021updated 12 Jul 2022 11:05am

Quantum Computing and IPQ collaborate to boost clinical trial outcomes

The new approach could enable the recovery of failed trials and improve study design.

Quantum Computing (QCI) and IPQ Analytics have collaborated on a new technique that can enhance the efficiency and outcomes of clinical trials and diagnostics.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

As part of the alliance, IPQ will examine real-world data to create new disease models via the integration of its knowledge graph depiction of the patient journey with QCI’s quantum-driven community detection technology.

The review of complex networks that imitate biological processes and molecular interactions is necessary for drug development, QCI noted.

In addition, understanding these networks’ structure and identifying interconnected communities play an important role.

Graph analytics can aid in assessing patient symptoms and outcomes for medical analysis.

QCI’s QGraph, a Qatalyst component, helps drug analysts address the computationally expensive graph issues.

With the collaboration, IPQ will have early access to the QGraph’s QDetect community-detection technology. This will enable ‘next-generation phenotypes’ (NGP) to re-diagnose participants in failed clinical trials to recognise responsive patient subgroups.

NGP can also be used for optimising payor reimbursement guidelines to decrease testing that is not required and ineffective treatment of patients.

It can further improve clinical decision support for early, precise diagnoses and enhanced patient management.

Estimates show that on average, clinical trials cost $1bn but less than 15% are successful.

For pharmaceutical organisations, the new IPQ modelling technique plus Qatalyst is expected to facilitate recovery of failed trials and improving study design.

The approach could allow improved patient diagnosis, treatment and outcomes.

Quantum Computing CEO Robert Liscouski said: “We believe that this new approach, optimised and enhanced with our quantum computing software, has significant clinical and commercial value.

“By enabling more effective patient management and the development of more directed and cost-effective treatments, we are committed to providing value with quantum computing for businesses today.”

The partners will use the new approach created and confirmed by IPQ for reserved ejection heart failure (HFpEF).

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena